Okada K, Sakata H, Minamoto A, Fujihara M
Department of Ophthalmology, Hiroshima University School of Medicine, Japan.
Ophthalmologica. 1996;210(3):175-9. doi: 10.1159/000310702.
The immunosuppressive effect of FK 506 on penetrating keratoplasty in rats was evaluated following intramuscular and topical administration. Implanted corneal grafts were inspected weekly by clinical evaluation for 3 weeks. Cytotoxic T lymphocyte (CTL) activity was measured in the spleen on postoperative day 21, and the grafts were examined histologically. A dose of FK 506, 0.1 mg/kg given intramuscularly, only moderately suppressed CTL activity and the graft failed. In contrast, doses of either 0.024 mg/day topically or 0.3 mg/kg intramuscularly suppressed CTL activity and the grafts remained intact. Results suggest that FK 506 administered topically would be effective in preventing failure of human corneal grafts.
通过肌肉注射和局部给药评估FK 506对大鼠穿透性角膜移植的免疫抑制作用。每周通过临床评估对植入的角膜移植物进行3周检查。在术后第21天测量脾脏中的细胞毒性T淋巴细胞（CTL）活性，并对移植物进行组织学检查。肌肉注射剂量为0.1 mg/kg的FK 506仅适度抑制CTL活性，移植物失败。相比之下，局部给药剂量为0.024 mg/天或肌肉注射剂量为0.3 mg/kg可抑制CTL活性，移植物保持完整。结果表明，局部应用FK 506可有效预防人类角膜移植失败。
